Discover why Lyell Immunopharma (LYEL) stock is up 191% YTD. Explore CAR T therapy breakthroughs, trial milestones, and key investment insights.

Equity Insider News Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion ...

Using the Pinnacle promo code 'COVERS' during registration will grant you access to the best odds and loads of exciting features such as full and partial cashout, betting stats, informative tutorials, ...

The Nebraska men's basketball team (6-0) will open a four-game home stand as the Huskers host the Winthrop Eagles (3-3) at Pinacle Bank Arena. The Huskers enter Tuesday's game with a 10-game win ...

Pinnacle has been known as a leader in the field of sports betting since its launch in 1998. As well as being renowned for providing great value to all sports fans, this operator was also an early ...

The abrupt departure of Lyell Immunopharma’s chief financial officer has created uncertainty about the biotechnology firm’s strategic direction during a pivotal period in its development. Charles ...

NEW YORK – Lyell Immunopharma on Wednesday said it will pit its autologous CD19/CD20-targeted CAR T-cell therapy rondecabtagene autoleucel (ronde-cel) against currently marketed cell therapies in a ...

PINACLE Connect embedded services enable corporate clients to access treasury functions within Oracle Fusion without switching platforms PNC Bank has integrated its PINACLE Connect embedded banking ...

PITTSBURGH - PNC Bank announced Tuesday the integration of its PINACLE Connect embedded banking platform with Oracle Fusion Cloud Enterprise Resource Planning (ERP), enabling corporate and commercial ...

ERP systems sit at the heart of the enterprise, circulating critical financial and operational data across an organization’s core business functions. Cloud adoption helped expand ERP capabilities and ...

Lyell Immunopharma's LYL314 CAR-T therapy shows high, durable response rates in 3rd-line + Large B-Cell Lymphoma patients. The company has initiated a phase 3 trial for LYL314 in 3rd-line + LBCL ...

Lyell Immunopharma has reported new clinical data from the Phase I/II clinical trial of autologous dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate, LYL314, along with ...